Project Grant R21AI197144
- Federal Grant Award Summary Cornell University's Office of Sponsored Programs received a $653,742 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded April 7, 2026, with completion targeted for March 31, 2031. The award supports research to elucidate the molecular mechanisms of maternal antibody interference with oral rotavirus vaccination, a critical barrier to vaccine efficacy...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston University Medical Campus a $176,738 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective September 1, 2025, through August 31, 2030. This award supports a mentoring and capacity-building initiative focused on training junior investigators from the United States and low-income countries (LICs) in patient-oriented research (POR) related to...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Virginia $242,250 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a Project Grant with an award date of April 10, 2026, and an ultimate completion date of March 31, 2028. This research initiative, titled "Microbial Drivers of Oral Vaccine Failure," investigates the mechanistic relationship between gut microbiota composition and the reduced...
- Federal Project Grant Award Summary Cincinnati Children's Hospital Medical Center received a $458,250 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 4, 2025, with completion targeted for August 31, 2027. The project focuses on developing and advancing a VP4-based pseudovirus nanoparticle (S-VP4E) rotavirus vaccine for oral immunization. Rotavirus causes severe...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital a $3.86 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective February 6, 2026, through January 31, 2030. The MARVELOUS (Maternal RSV Vaccination—Evaluating Optimal Immune Responses) study investigates immune responses to respiratory syncytial virus (RSV) vaccination administered during pregnancy, with particular...
- Federal Project Grant Award Summary Baylor College of Medicine received a $240,000 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 1, 2026 through March 31, 2028. The award supports research aimed at understanding rotavirus pathogenesis mechanisms and vaccine development. Specifically, the funded research defines the structural and functional characteristics of...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Harvard College's Office for Sponsored Programs a $414,029 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 19, 2026, with a completion date of January 31, 2031. This award supports advanced research aimed at understanding programmed ribosomal frameshifting mechanisms in coronaviruses, specifically how these viruses manipulate gene expression...
- Federal Grant Award Summary Boston University, through its Medical Campus in Roxbury, Massachusetts, received a $2,010,240 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective December 1, 2025, through November 30, 2029. The project will investigate the determinants of poor immune responsiveness to the booster dose of the RTS,S malaria vaccine in African children. The...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Harvard College's Office for Sponsored Programs a $916,436 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective February 5, 2026, with a completion date of January 31, 2031. This award supports research in human thymus engineering aimed at developing scalable methods for producing functional, antigen-specific T cells derived from induced pluripotent...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital a Project Grant of $489,500 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 24, 2025, with a completion date of June 30, 2027. The award funds structural research aimed at determining the high-resolution three-dimensional structure of the full-length nucleocapsid (N) protein of Severe Acute Respiratory Syndrome Coronavirus 2...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $228,000 Project Grant to Harvard College's T.H. Chan School of Public Health, with performance from April 1, 2026 through March 31, 2028, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This research initiative will investigate the relationship between maternal and infant micronutrient deficiencies—specifically iron, zinc, vitamin A, and vitamin D—and reduced immune response to oral rotavirus vaccines in low-resource settings. The study addresses a critical public health gap, as oral rotavirus vaccines demonstrate significantly lower efficacy (40%-64%) in sub-Saharan Africa and South Asia compared to high and middle-income countries (85%-98%), despite WHO recommendations for universal childhood vaccination against rotavirus, a leading cause of severe childhood diarrhea and mortality worldwide. The research will evaluate plasma samples from 250 mother-infant pairs obtained through a completed randomized, placebo-controlled vaccine efficacy trial conducted in Niger. By analyzing the associations between the four targeted micronutrients and infants' failure to develop effective immune responses, this study aims to identify the biological mechanisms underlying vaccine underperformance and generate evidence that could enhance oral vaccine efficacy in low-resource populations through targeted micronutrient interventions or other evidence-based public health strategies.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 4/10/26 | ||
| Not listed | $228.0k | 3/27/26 |